ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0642

COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies

Marta González Fernández1, Orlando Pompei fernández2, Joaquín María Belzunegui Otano3, Paula García Escudero1, Claudia Stoye2, Juan Ramón De Dios2, Belén Álvarez Rodríguez2, Elena Garmendia Sánchez1, Susana Gil2, Ana Ruibal-Escribano4, Margarida Vasques Rocha2, Francisco García Llorente5, César Antonio Egües6, Edurne Guerrero7 and Jaime Calvo-Alén2, 1Hospital Universitario Cruces, Barakaldo, Spain, 2Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, 3Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, 4Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, 5Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, 6Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, 7Hospital Alto Deba, Arrasate, Pais Vasco, Spain

Meeting: ACR Convergence 2020

Keywords: Anti-TNF Drugs, Biologicals, Disease-Modifying Antirheumatic Drugs (Dmards), Infection, population studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two ways: in the one hand, due to the use, in its treatment, of specific agents usually indicated in rheumatologic conditions and, on the other hand, the fear that our patients could be at higher risk due to the use of immunosuppressive agents.
The main objective of our study was to analyze the incidence of COVID infection in rheumatologic patients on treatment with targeted therapies (TT) (b and stDMARD) and to compare the incidence of such infection in the general population.

Methods: All patients with rheumatologic inflammatory conditions and COVID infection (confirmed by PCR of nasopharyngeal swab or serology) followed at three university referral centers from Basque Country (Spain) were identified. Patients on treatment with TT were selected. Characteristics of rheumatologic condition, type of TT and outcome of the infection were registered. Infection rates with the different TT were calculated and compared with the general population.

Results: Among 97 rheumatologic patients with COVID-19 infection 19 (12 with TNFi, 2 with anti-IL6 and 1 with abatacept, rituximab, ustekinumab, anakinra and baricitinib) were on treatment with TT at the COVID-19 infection diagnosis. Although, no significant differences were observed with those not taking TT with regards to severe disease outcome (hospital admission or death), the admission rate was 31.8% (greater than that commonly reported in general population ≈ 20%) and the mortality rate 13.8%, higher than that observed in our region (7.8%). In comparison with the general population of our region, the total infection rate for patients on TT was 4% vs 0.9%.

Specifically, in those taking TNFi the infection rate was of 3.5% and in those taking anti-IL6 of 3.1%.

Conclusion: Rheumatologic patients taking TT present higher rates of COVID infection than those seem in the general population (under the same criteria for infection definition). The admission rates observed in these patients suggest also a more severe course of the infection.


Disclosure: M. González Fernández, None; O. Pompei fernández, None; J. Belzunegui Otano, None; P. García Escudero, None; C. Stoye, None; J. De Dios, None; B. Álvarez Rodríguez, None; E. Garmendia Sánchez, None; S. Gil, None; A. Ruibal-Escribano, None; M. Vasques Rocha, None; F. García Llorente, None; C. Egües, None; E. Guerrero, None; J. Calvo-Alén, None.

To cite this abstract in AMA style:

González Fernández M, Pompei fernández O, Belzunegui Otano J, García Escudero P, Stoye C, De Dios J, Álvarez Rodríguez B, Garmendia Sánchez E, Gil S, Ruibal-Escribano A, Vasques Rocha M, García Llorente F, Egües C, Guerrero E, Calvo-Alén J. COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/covid-19-infection-in-rheumatologic-patients-on-treatment-with-targeted-therapies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/covid-19-infection-in-rheumatologic-patients-on-treatment-with-targeted-therapies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology